- Home
- BFH vs MLYS Comparison
BFH vs MLYS Comparison
Compare BFH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFH
- MLYS
- Stock Information
- Founded
- BFH 1996
- MLYS 2019
- Country
- BFH United States
- MLYS United States
- Employees
- BFH N/A
- MLYS N/A
- Industry
- BFH Business Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- BFH Consumer Discretionary
- MLYS Health Care
- Exchange
- BFH Nasdaq
- MLYS Nasdaq
- Market Cap
- BFH 3.0B
- MLYS 2.9B
- IPO Year
- BFH N/A
- MLYS 2023
- Fundamental
- Price
- BFH $68.22
- MLYS $43.37
- Analyst Decision
- BFH Hold
- MLYS Strong Buy
- Analyst Count
- BFH 15
- MLYS 6
- Target Price
- BFH $65.29
- MLYS $46.40
- AVG Volume (30 Days)
- BFH 713.3K
- MLYS 1.9M
- Earning Date
- BFH 10-23-2025
- MLYS 11-10-2025
- Dividend Yield
- BFH 1.38%
- MLYS N/A
- EPS Growth
- BFH 55.00
- MLYS N/A
- EPS
- BFH 9.68
- MLYS N/A
- Revenue
- BFH $2,509,000,000.00
- MLYS N/A
- Revenue This Year
- BFH $59.03
- MLYS N/A
- Revenue Next Year
- BFH $3.92
- MLYS N/A
- P/E Ratio
- BFH $6.84
- MLYS N/A
- Revenue Growth
- BFH 1.70
- MLYS N/A
- 52 Week Low
- BFH $38.21
- MLYS $8.24
- 52 Week High
- BFH $68.63
- MLYS $47.65
- Technical
- Relative Strength Index (RSI)
- BFH 67.01
- MLYS 54.88
- Support Level
- BFH $59.26
- MLYS $40.50
- Resistance Level
- BFH $65.83
- MLYS $43.90
- Average True Range (ATR)
- BFH 2.09
- MLYS 3.79
- MACD
- BFH 0.45
- MLYS -0.23
- Stochastic Oscillator
- BFH 95.35
- MLYS 69.54
About BFH Bread Financial Holdings Inc.
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.